New targeted drug aims to fight hard-to-treat bladder cancers
NCT ID NCT05544552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to standard treatments will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Cleveland Clinic - Main Campus
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Cancer Institute (DCI) - Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Gustave Roussy (Institut de Cancerologie Gustave-Roussy)
Villejuif, 94805, France
-
Institut Claudius Regaud, IUCT-Oncopole
Toulouse, 31059, France
-
Institut de Cancerologie de L'Ouest (ICO)
Saint-Herblain, 44805, France
-
Linear Clinical Research Limited
Nedlands, Washington, 6009, Australia
-
Macquarie University
Macquarie Park, New South Wales, 2109, Australia
-
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, New York, 10021, United States
-
NEXT Barcelona - Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
NEXT Madrid - Hospital Universitario Quironsalud Madrid
Madrid, 28223, Spain
-
Peter MacCallum Cancer Research Unit
Melbourne, Victoria, 3000, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Seattle Cancer Care Alliance (SCCA) - South Lake Union
Seattle, Washington, 98109, United States
-
Tasman Oncology
Southport, Queensland, 4215, Australia
-
UMass Memorial Medical Center
Worchester, Massachusetts, 01655, United States
-
Vall d'Hebron Institut d'Oncologia (VHIO)
Barcelona, 08035, Spain
-
Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can removing bladder tumors in one piece improve cancer outcomes?
- Can a new nucleotide analogue boost cancer treatment?
- Can an AI agent match expert urologists? a major test begins
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?